Protein-Protein Interaction and Aggregation Inhibitors in Alzheimer’s Disease

(E-pub Ahead of Print)

Author(s): Ankit Ganeshpurkar, Rayala Swetha, Devendra Kumar, Gore Pravin Gangaram, Ravi Singh, Gopichand Gutti, Srabanti Jana, Dileep Kumar, Ashok Kumar, Sushil Kumar Singh*.

Journal Name: Current Topics in Medicinal Chemistry

Become EABM
Become Reviewer

Abstract:

Background: Alzheimer’s disease (AD), a multifaceted disorder, involves complex pathophysiology and plethora of protein-protein interactions. Thus such interactions can be exploited to develop anti-AD drugs.

Objective: The interaction of dynamin-related protein 1, cellular prion protein, phosphoprotein phosphatase 2A and Mint2 with amyloid β etc., studied recently, may have critical role in progression of the disease. Our objective has been to review such studies and their implication in design and development of against the Alzheimer’s disease.

Method: Such studies have been reviewed and critically assessed.

Results: Review has led to show how such studies are useful to develop anti-AD drugs.

Conclusion: There are several PPIs which are current topic of research including Drp1, Aβ interactions with various targets including PrPC, Fyn kinase, NMDAR and mGluR5 and interaction of Mint2 with PDZ domain, etc., and thus have potential role in neurodegeneration and AD. Finally, the multi-targeted approach in AD may be fruitful and opens a new vista for identification and targeting of PPIs in various cellular pathways to find a cure for the disease.

Keywords: Alzheimer’s disease, Protein-protein interactions, Amyloid beta, Tau, BACE1, Mint2, peptidomimetics, small molecule inhibitors.

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1568026619666190304153353
Price: $95

Article Metrics

PDF: 1